Cannabis use in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials (RCTs).

Objective: This meta-analysis aims to systematically evaluate the efficacy and safety of cannabis in the management of Crohn's disease (CD) by synthesizing evidence from randomized controlled trials (RCTs). By adhering to the 2020 PRISMA guidelines and registering the study protocol with PROSPERO, this research intends to offer robust, evidence-based recommendations for healthcare practitioners on the therapeutic potential and clinical implications of cannabis use in CD management.

Methods: A literature search encompassing PubMed, Google Scholar, and the Cochrane Library was conducted to identify relevant RCTs comparing cannabis to placebo or standard therapy in CD patients.

Revolutionizing Cardiac Care: Artificial Intelligence Applications in Heart Failure Management.

Recent advancements in artificial intelligence (AI) have revolutionized the diagnosis, risk assessment, and treatment of heart failure (HF). AI models have demonstrated superior performance in distinguishing healthy individuals from those at risk of congestive HF by analyzing heart rate variability data. In addition, AI clinical decision support systems exhibit high concordance rates with HF experts, enhancing diagnostic precision.

Effects of a multimedia campaign to increase human papillomavirus vaccine acceptance in Dhaka, Bangladesh.

Increasing the uptake of Human Papillomavirus (HPV) vaccine among adolescent girls is a high priority for the government of Bangladesh. This study examines correlates of HPV vaccine adoption in Dhaka Division, the largest division in Bangladesh. The 18-day vaccination campaign was accompanied by multimedia messages.

Cross-sectional study exploring the prevalence and clinical manifestations of acute diarrhea among under-5 children in primary care hospital in Democratic Republic of the Congo.

Background: Acute diarrhea (AD), which is defined as frequent passing of liquid stools compared to normal, is a serious and worrying problem and remains a concern for healthcare systems because of its high mortality cause in children under 5 years old. The authors' study aimed to present the prevalence and to describe the clinical manifestation of AD among under-5 children.

Methods: From June 2022 to May 2023, the authors conducted a retrospective, descriptive and cross-sectional study including all patients aged 0-5 years hospitalized for AD.